论文部分内容阅读
目的:评价达沙替尼联合多药化疗方案在Ph染色体阳性急性淋巴细胞白血病（Phn + ALL）患者中的疗效及安全性。n 方法:前瞻性、单臂、开放的临床研究。2016年1月至2018年4月中国医学科学院血液病医院收治的30例初诊成人Phn + ALL患者入组。采用多药化疗方案，标准诱导化疗为期4周，自诱导化疗第8天开始口服达沙替尼（商品名依尼舒，正大天晴药业集团股份有限公司产品）100 mg/d，持续应用至整体治疗结束。有条件和意愿进行移植者，可进行异基因造血干细胞移植或自体造血干细胞移植。n 结果:所有30例患者在诱导治疗4周后均达到血液学完全缓解（HCR），累积完全分子学反应（MCR）率为70.0%（21/30）。中位随访时间为37.8（32.0~46.6）个月。3年总生存（OS）率为68.1%，3年无血液学复发生存（HRFS）率为61.6%。63.3%的患者在治疗3个月时达到主要分子学反应（MMR）（其中有43.3%患者达到MCR）。6个月时60.0%的患者达到MCR，达到MCR的患者具有更好的OS（n P=0.004）、HRFS（n P=0.049）和EFS（n P=0.001）。15例（50.0%）患者在第1次HCR期内进行移植，移植组患者HRFS（n P=0.030）和EFS（n P=0.010）优于化疗组。n 结论:达沙替尼联合多药化疗方案治疗初诊Phn +ALL安全有效。n 临床试验注册:ClinicalTrials.gov，NCT02523976。“,”Objective:This study evaluates the efficacy and safety of dasatinib combined with a multi-agent chemotherapy regimen of Philadelphia chromosome-positive acute lymphoblastic leukemia (Phn + ALL) patients.n Methods:This prospective, single-arm, and open clinical study enrolled 30 adult Phn + ALL patients who were newly diagnosed and treated from January 2016 to April 2018 in the center of this study. Standard induction chemotherapy was given for 4 weeks. However, dasatinib (100 mg/d) was continuously administered from day 8 until the end of the whole therapy in the induction therapy. Patients who are available for allogeneic or autologous stem cell transplantation (SCT) received transplantation when the disease was evaluated as complete remission.n Results:All 30 patients achieved hematological complete remission (HCR) after the induction chemotherapy, and 70.0% (21/30) of them achieved the accumulated molecular complete remission (MCR) . The patients were followed up with a median follow-up time of 37.8 months (32.0-46.6) . The 3 year overall survival (OS) and 3 year hematological relapse-free survival (HRFS) were 68.1% and 61.6%, respectively. Moreover, 63.3% and 43.3% of the patients achieved molecular major remission and MCR, respectively. Consequently, 60.0% of the patients achieved MCR until 6 months. The patients who achieved MCR within 6 months had superior OS (n P=0.004) , HRFS (n P=0.049) , and event-free survival (EFS; n P=0.001) . Fifteen patients (50.0%) received SCT at the first HCR. However, HRFS (n P=0.030) and EFS (n P=0.010) in the SCT group were better than those in the chemotherapy group.n Conclusions:The regimen of dasatinib combined with a multi-agent chemotherapy was proven safe and effective in the treatment of newly diagnosed adult Phn + ALL patients.n Clinical trial registration:ClinicalTrials.gov, NCT02523976.